Conclusions
While Pentostatin was well-tolerated in this study, the dose and schedule of drug administration were ineffective. Since this study basically involved patients that had not experienced prior systemic therapy, it is concluded that Pentostatin is ineffective in the treatment of metastatic malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. Journal of Clinical Oncology 7:168–172, 1989
Grever MR, Leiby JM, Kraut EH, Wilson HE, Neidhart JA, Wall RL, Balcerzak SP: Low dose deoxycoformycin in lymphoid malignancy. Journal of Clinical Oncology 3:1196–1201, 1985
Grever MR, Bisaccia E, Scarborough DA, Metz EN, Neidhart JA: An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61:279–283, 1983
Grever MR, Chapman RA, Ratanatharathorn V, Slease RB: An investigation of 2′-deoxycoformycin in advanced cutaneous T-cell lymphoma (A Southwest Oncology Group Study). Blood 66 (Suppl. 1):215a, 1985 (Abstr)
Grever MR, Coleman MS, Gray DP, Malspeis, L, Balcerzak SP, Neidhart JA: Definition of a safe yet effective dosing regimen in 2′-deoxycoformycin with biological evaluation. Cancer Treatment Symposium 2:97–103, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grever, M., Brager, P., Kraut, E. et al. A phase II investigation of pentostatin in metastatic malignant melanoma. Invest New Drugs 10, 345–346 (1992). https://doi.org/10.1007/BF00944193
Issue Date:
DOI: https://doi.org/10.1007/BF00944193